Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating approximately $8.5 billion across drug discovery, clinical development, and commercialization. The surge reflects the growing recognition that AI is no longer a niche tool but a strategic driver across the entire biopharma value chain.
2025: Key AI Investments and Strategic Deals
Major deals and collaborations in 2025 illustrate how AI is transforming biopharma operations:
- Pfizer expanded its AI collaboration with PostEra, focusing on AI-driven medicinal chemistry and antibody-drug conjugate design, with total deal value exceeding $120 million in upfront and milestone commitments.
- Eli Lilly signed a $105 million research pact with Insilico Medicine to apply AI techniques to drug discovery, while also partnering with NVIDIA to build one of pharma’s most powerful AI supercomputers for preclinical modeling.
- Roche invested $85 million to license AI tools from Manifold Bio for development of brain-penetrant therapeutics.
- Additional strategic partnerships involving Takeda, Novartis, and emerging AI-focused biotech firms added another $200 million in AI-related funding in 2025.
Overall, AI-driven collaborations and internal platform investments in 2025 totaled over $8.5 billion, reflecting the prioritization of AI across discovery, R&D, and commercialization.
AI Across the Biopharma Value Chain
- Discovery: Generative AI and multi-omic analytics accelerated target identification, compound design, and predictive modeling.
- R&D: AI optimized trial design, patient recruitment, and digital biomarker integration, reducing projected clinical development timelines by 10–15% in key programs.
- Commercialization: Predictive analytics and market access AI tools enhanced pricing strategy, payer segmentation, and real-world evidence generation, improving launch efficiency and patient access.
2026 Outlook: Scale, Integration, and Market Impact
Looking ahead, AI investment is expected to grow by 15–20% in 2026, with focus areas including:
- Integrated AI platforms connecting discovery, development, and commercialization data for end-to-end optimization.
- Regulatory alignment enabling AI-augmented submissions and faster review timelines.
- Value-based pricing strategies leveraging AI-generated real-world evidence.
- Strategic M&A and partnerships, as companies with mature AI capabilities attract acquisitions and investment.
As biopharma enters 2026, AI is moving from experimental projects to core enterprise capability, positioning companies to accelerate innovation, reduce risk, and enhance patient outcomes across therapeutic areas.
By